HomeCompareNUAN vs ABBV

NUAN vs ABBV: Dividend Comparison 2026

NUAN yields 3.57% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $77.1K in total portfolio value
10 years
NUAN
NUAN
● Live price
3.57%
Share price
$55.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.2K
Annual income
$449.44
Full NUAN calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — NUAN vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNUANABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NUAN + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NUAN pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NUAN
Annual income on $10K today (after 15% tax)
$303.63/yr
After 10yr DRIP, annual income (after tax)
$382.02/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,673.98/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NUAN + ABBV for your $10,000?

NUAN: 50%ABBV: 50%
100% ABBV50/50100% NUAN
Portfolio after 10yr
$63.8K
Annual income
$12,610.60/yr
Blended yield
19.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NUAN
Analyst Ratings
8
Buy
8
Hold
1
Sell
Consensus: Buy
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NUAN buys
0
ABBV buys
0
No recent congressional trades found for NUAN or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNUANABBV
Forward yield3.57%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$25.2K$102.3K
Annual income after 10y$449.44$24,771.77
Total dividends collected$4.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: NUAN vs ABBV ($10,000, DRIP)

YearNUAN PortfolioNUAN Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,057$357.21$11,550$430.00$493.00ABBV
2$12,200$369.13$13,472$627.96$1.3KABBV
3$13,435$380.65$15,906$926.08$2.5KABBV
4$14,767$391.75$19,071$1,382.55$4.3KABBV
5$16,203$402.42$23,302$2,095.81$7.1KABBV
6$17,750$412.67$29,150$3,237.93$11.4KABBV
7$19,415$422.49$37,536$5,121.41$18.1KABBV
8$21,206$431.89$50,079$8,338.38$28.9KABBV
9$23,132$440.87$69,753$14,065.80$46.6KABBV
10$25,200$449.44$102,337$24,771.77$77.1KABBV

NUAN vs ABBV: Complete Analysis 2026

NUANStock

Nuance Communications, Inc. provides conversational and cognitive artificial intelligence (AI) innovations that bring intelligence to everyday work and life. The company delivers solutions that understand, analyze, and respond to people - amplifying human intelligence to increase productivity and security. Its Healthcare segment provides clinical speech and clinical language understanding solutions that improve the clinical documentation process, from capturing the complete patient record to improving clinical documentation and quality measures for reimbursement. Its solutions include Dragon Medical One, cloud-based speech solution; computer-assisted physician documentation; diagnostic imaging solutions; Nuance Dragon Ambient eXperience, a voice-enabled solution; and clinical documentation improvement and coding. The company's Enterprise segment primarily engages in using speech, natural language understanding, and artificial intelligence to provide automated customer solutions and services for voice, mobile, web, and messaging channels. Its solutions include intelligent engagement solutions; Conversational AI; Engagement AI; and Security AI. Its Other segment provides voicemail transcription services. It serves organizations across healthcare, financial services, telecommunications, government, and retail. The company markets and sells its solutions and technologies directly through sales force, as well as through a network of resellers, including system integrators, independent software vendors, value-added resellers, distributors, hardware vendors, telecommunications carriers, and e-commerce Websites worldwide. The company was formerly known as ScanSoft, Inc. and changed its name to Nuance Communications, Inc. in October 2005. Nuance Communications, Inc. was incorporated in 1992 and is headquartered in Burlington, Massachusetts. As of March 4, 2022, Nuance Communications, Inc. operates as a subsidiary of Microsoft Corporation.

Full NUAN Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NUAN vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NUAN vs SCHDNUAN vs JEPINUAN vs ONUAN vs KONUAN vs MAINNUAN vs JNJNUAN vs MRKNUAN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.